15 completed, 4 withdrawn, 2 terminated, 1 not yet recruiting. 7 Phase 2, 6 Phase 1, 4 Not applicable, 4 Phase 4, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Withdrawn 2, Terminated 1 |
| Phase 1 | 6 | Completed 4, Withdrawn 2 |
| Not applicable | 4 | Completed 3, Withdrawn 1 |
| Phase 4 | 4 | Completed 4 |
| Early Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow FS 069: new trials by email Literature Review of FS 069 trials Research Report on FS 069
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function Ultrasound contrast agent (Contrast-enhanced ultrasound), Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Lumason® contrast agent - End Stage Chronic Renal Failure, Renal Transplant | Not yet recruiting | Roderick Tan | 40 | 2026-06-01 | 2026-06-12 | |
| Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema Lumason, Optison, Definity - Lymphedema Arm | Phase 1 | Completed | Mayo Clinic | 10 | 2022-12-15 | 2024-08-21 |
| Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment Perflutren Protein-Type A Microspheres, Contrast-Enhanced Ultrasound - Intrahepatic Cholangiocarcinoma | Phase 2 | Completed | Thomas Jefferson University | 16 | 2021-12-14 | 2025-10-28 |
| Study to Determine Safety and Dosage of OPTISON in Pediatric Participants Optison - Transthoracic Echocardiography, Suspected or Known Structural or Functional Cardiac Abnormality | Phase 4 | Completed | GE Healthcare | 39 | 2020-12-01 | 2024-05-17 |
| Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial percutaneous intervention (PCI), Microbubbles, Ultrasound - STEMI, Chest Pain | Not applicable | Completed | University of Nebraska | 50 | 2018-09-16 | 2023-10-31 |
| Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer Yttrium-90 Microsphere Radioembolization, Perflutren Protein-Type A Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging - Hepatocellular Carcinoma | Phase 2 | Completed | Thomas Jefferson University | 104 | 2017-07-01 | 2026-01-02 |
| IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys? Optison, Ultrasound (US), Contrast-enhanced ultrasound (CEUS) - Transplantation, Kidney | Phase 4 | Completed | Mayo Clinic | 40 | 2015-11-01 | 2020-03-02 |
| Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients Perflutren Protein-Type A Microspheres Injectable Suspension, Contrast-Enhanced Ultrasound (CEUS), Biopsy + Radioactive Seed Placement - Breast Cancer | Not applicable | Completed | M.D. Anderson Cancer Center | 21 | 2015-07-01 | 2017-06-20 |
| Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation Optison - Renal Cell Carcinoma | Phase 2 | Completed | Thomas Jefferson University | 53 | 2015-04-23 | 2025-05-04 |
| Contrast-Enhanced Ultrasound in Human Crohn's Disease Contrast Enhanced Ultrasound, Optison - Crohn's Disease | Phase 1 / Phase 2 | Withdrawn | University of Michigan | 2015-02-01 | 2015-06-15 | |
| Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection Optison - Heart Transplantation | Terminated | Brigham and Women's Hospital | 10 | 2015-01-01 | 2023-07-27 | |
| CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children OPTISON - Vesico-Ureteral Reflux | Phase 1 / Phase 2 | Completed | Kassa Darge | 31 | 2014-07-01 | 2018-11-27 |
| Contrast Enhanced Ultrasound for Evaluation of Pediatric Abdominal Trauma Contrast enhanced Ultrasound - Abdominal Trauma | Phase 1 | Completed | David Mooney | 18 | 2013-04-01 | 2017-01-31 |
| Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery Perflutren Protein-Type A Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging - Renal Cell Carcinoma | Early Phase 1 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-01-24 | 2025-05-02 | |
| Regadenoson Real Time Perfusion Imaging Trial-Optison Regadenoson; Optison - Coronary Artery Disease, Myocardial Perfusion Abnormalities | Phase 3 | Completed | University of Nebraska | 50 | 2012-07-31 | 2024-10-08 |
| Detection of Coronary Stenosis With Intravenous Microbubbles Optison, Definity, PESDA - Coronary Stenosis, Carotid Stenosis | Not applicable | Withdrawn | University of Nebraska | 2012-02-01 | 2024-09-23 | |
| Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease Optison - Carotid Artery Disease | Phase 2 | Terminated | GE Healthcare | 21 | 2011-06-01 | 2014-05-02 |
| Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR). Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose - Pulmonary Hypertension | Phase 4 | Completed | GE Healthcare | 30 | 2009-03-01 | 2012-08-24 |
| A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice. Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP) - Echocardiography | Phase 4 | Completed | GE Healthcare | 1039 | 2008-05-01 | 2012-06-12 |
| Assessing Myocardial Blood Flow and Blood Flow Reserve by Transoesophageal Echocardiography (TEE) SonoVue, Optison - Coronary Artery Disease | Phase 1 / Phase 2 | Withdrawn | University Hospital, Basel, Switzerland | 2006-08-01 | 2015-03-25 |
Showing 20 of 22. Sign in to see all of them.
Carcinoma, Renal Cell (2) · Coronary Artery Disease (2) · Abdominal Injuries (1) · Abdominal Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carotid Artery Diseases (1) · Carotid Stenosis (1) · Chest Pain (1) · Cholangiocarcinoma (1) · Coronary Stenosis (1) · Crohn Disease (1) · Delayed Graft Function (1) · Hypertension, Pulmonary (1) · Pelvic Neoplasms (1)
GE Healthcare (4) · University of Nebraska (4) · Thomas Jefferson University (3) · Mayo Clinic (2) · Brigham and Women's Hospital (1) · David Mooney (1) · Kassa Darge (1) · M.D. Anderson Cancer Center (1) · Roderick Tan (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · St. Jude Children's Research Hospital (1) · University Hospital, Basel, Switzerland (1) · University of Michigan (1)
United States (19) · Brazil (1) · Netherlands (1)
Thomas R Porter, MD (4) · Andrea Perrone, M.D. (1) · Basak Dogan, MD (1) · Christine Lee, MD, PhD (1) · Christopher Jefferds (1) · David Thompson, MD, PhD (1) · Flemming Forsberg, PhD (1) · J Kriegshauser, MD (1) · Jill Zalieckas, MD (1) · John Eisenbrey, PhD (1) · Kassa Darge, MD, PhD (1) · Manfred D Seeberger, Prof. Dr. (1) · Mary E. McCarville, M.D. (1) · Michael Givertz, MD (1) · Rubin Sheng, MD (1)
PMID 25882093, PMID 26109588, PMID 27742126, PMID 41025990
R01CA238241 (1), R21CA259750 (1)